These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 27640873)

  • 1. Extended half-life factor VIII for immune tolerance induction in haemophilia.
    Malec LM; Journeycake J; Ragni MV
    Haemophilia; 2016 Nov; 22(6):e552-e554. PubMed ID: 27640873
    [No Abstract]   [Full Text] [Related]  

  • 2. What is the role of an extended half-life product in immune tolerance induction in a patient with severe hemophilia A and high-titer inhibitors?
    Janbain M; Pipe S
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):648-649. PubMed ID: 27913541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-dose pharmacokinetics of porcine factor VIII (Hyate C).
    Hermans C; Owens D; Longo G; Morfini M; Lee CA
    Thromb Haemost; 2002 Feb; 87(2):352-3. PubMed ID: 11858504
    [No Abstract]   [Full Text] [Related]  

  • 4. Immune tolerance therapy for haemophilia A patients with acquired factor VIII alloantibodies: comprehensive analysis of experience at a single institution.
    Smith MP; Spence KJ; Waters EL; Beresford-Webb R; Mitchell MJ; Cuttler J; Alhaq A; Brown SA; Savidge GF
    Thromb Haemost; 1999 Jan; 81(1):35-8. PubMed ID: 9974371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Domain specificity of factor VIII inhibitors during immune tolerance induction in patients with haemophilia A.
    van Helden PM; Kaijen PH; Mauser-Bunschoten EP; Fischer K; van den Berg HM; Voorberg J
    Haemophilia; 2010 Nov; 16(6):892-901. PubMed ID: 20491952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haemostatic response to factor VIII administration in patients with haemophilia A measured by thrombin generation and correlation with factor concentrate use.
    Hugenholtz GC; Luddington R; Baglin T
    Haemophilia; 2016 Jan; 22(1):e42-5. PubMed ID: 26388112
    [No Abstract]   [Full Text] [Related]  

  • 7. Low-titre inhibitors, undetectable by the Nijmegen assay, reduce factor VIII half-life after immune tolerance induction.
    Dardikh M; Albert T; Masereeuw R; Oldenburg J; Novakova I; van Heerde WL; Verbruggen B
    J Thromb Haemost; 2012 Apr; 10(4):706-8. PubMed ID: 22284849
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of factor VIII after inhibitor clearance in patients with moderate haemophilia A: a case series.
    Tran DQ; Harvey RD; Meeks SL; Chapman R; Kempton CL
    Haemophilia; 2014 Jul; 20(4):e344-6. PubMed ID: 24750497
    [No Abstract]   [Full Text] [Related]  

  • 9. Determination of pharmacokinetics of replacement factor VIII.
    Mannucci PM; Morfini M
    Semin Hematol; 1990 Apr; 27(2 Suppl 2):8-10. PubMed ID: 2128856
    [No Abstract]   [Full Text] [Related]  

  • 10. Heat inactivation of extended half-life factor VIII concentrates.
    Fylling KA; Tange JI; Chen D; Pruthi RK
    Haemophilia; 2019 Mar; 25(2):e130-e131. PubMed ID: 30748064
    [No Abstract]   [Full Text] [Related]  

  • 11. The German National Immune Tolerance Registry, 1997 update. Study Group of German Haemophilia Centres.
    Lenk H
    Vox Sang; 1999; 77 Suppl 1():28-30. PubMed ID: 10529683
    [No Abstract]   [Full Text] [Related]  

  • 12. Immune tolerance induction with a factor VIII concentrate containing von Willebrand factor (Haemoctin SDH®) in 14 patients with severe haemophilia A.
    Bidlingmaier C; Kurnik K; Escuriola-Ettingshausen C; Jager R; Klamroth R; Male C; Marosi A; Nemes L; von Stackelberg A; Kreuz W
    Haemophilia; 2011 Sep; 17(5):e837-40. PubMed ID: 21649797
    [No Abstract]   [Full Text] [Related]  

  • 13. Spontaneous disappearance of high titre factor VIII inhibitor 15 years after unsuccessful ITI.
    Thom K; Male C; Falger J; Pabinger I
    Hamostaseologie; 2009 May; 29(2):149-50. PubMed ID: 19404512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FVIII dosages in persons with haemophilia A treated with extended half-life products: From local biology to optimized patient management.
    Perrier-Cornet A; Philippe A; Lambert T; d'Oiron R; Rafowicz A; Lavenu-Bombled C; Combe S; Gillibert A; Proulle V
    Haemophilia; 2019 Nov; 25(6):e361-e363. PubMed ID: 31206947
    [No Abstract]   [Full Text] [Related]  

  • 15. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.
    Kreuz W; Escuriola Ettingshausen C; Vdovin V; Zozulya N; Plyushch O; Svirin P; Andreeva T; Bubanská E; Campos M; Benedik-Dolničar M; Jiménez-Yuste V; Kitanovski L; Klukowska A; Momot A; Osmulskaya N; Prieto M; Šalek SZ; Velasco F; Pavlova A; Oldenburg J; Knaub S; Jansen M; Belyanskaya L; Walter O; ;
    Haemophilia; 2016 Jan; 22(1):87-95. PubMed ID: 26202305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experience with a third generation recombinant factor VIII concentrate (Advate) for immune tolerance induction in patients with haemophilia A.
    Valentino LA; Recht M; Dipaola J; Shapiro AD; Pipe SW; Ewing N; Urgo J; Bullock T; Simmons M; Deguzman C
    Haemophilia; 2009 May; 15(3):718-26. PubMed ID: 19298383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of factor VIII pharmacokinetics and anti-factor VIII antibodies in four boys with haemophilia A and a poor clinical response to factor VIII.
    Kempton CL; Meeks SL; Donald Harvey R; Abshire TC
    Haemophilia; 2011 Jan; 17(1):155-6. PubMed ID: 20579112
    [No Abstract]   [Full Text] [Related]  

  • 18. Hemophilic patients with an inhibitor to factor VIII treated with high dose factor VIII concentrate. Results of a collaborative study for the evaluation of factor VIII inhibitor titer, recovery and half life of infused factor VIII.
    Sultan Y; White GC; Aronstam A; Bosser C; Brackmann HH; Brochier G; Gormsen J; Mariani G; Roberts HR; Scarabin Y
    Nouv Rev Fr Hematol (1978); 1986; 28(2):85-9. PubMed ID: 3090516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of a premature infant with moderate haemophilia A using recombinant factor VIII.
    Gale RF; Hird MF; Colvin BT
    Haemophilia; 1998 Nov; 4(6):850-3. PubMed ID: 10028309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.
    Mahdi AJ; Obaji SG; Collins PW
    Br J Haematol; 2015 Jun; 169(6):768-76. PubMed ID: 25754016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.